Poppy processor Palla Pharma has agreed to pay $1.125 million to rival Tasmanian Alkaloids t0 settle a lawsuit alleging infringement of two innovation patents for high codeine-concentrated poppy.
A self-described “vigilant lawyer against big companies” has attempted to make submissions regarding the costs incurred in the Sirtex shareholder class action settlement, with legal fees and funders’ commissions chewing up half of the $40 million settlement figure. Maurice Blackburn took the lead after two shareholder class actions relating to the biotech company’s revised sales…
Global pharmaceutical giant Pfizer has successfully defended the patent for its sedative drug Precedex against a validity challenge, a big win for the drug maker after a US court found last year that its patents for a ready-to-use version of the drug were invalid for obviousness.
Israeli drug giant Teva and German drug maker Boehringer Ingelheim have settled their dispute over a patented capsule used to deliver the medicine in Boehringer’s top-selling inhaler Spiriva.
Group members in a class action against Johnson & Johnson unit DePuy International over allegedly defective hip implants are on track to receive 100 per cent of their claims as the $250 million settlement continues to be distributed, a court has heard.
A court has given the green light to a $1.1 million class action settlement with the owners of Sydney’s Quakers Hill Nursing Home over a fire deliberately lit by one of its employees in 2011.
A class action against the NSW government over a contractor who sold the personal details of 130 ambulance workers to personal injury law firms has flagged it may subpoena the founder and principal of Bannister Law, which purchased the confidential information.
A Federal Court judge has apologised for “upsetting the applecart” and taking “too long” to publish his judgment in the consumer regulator’s case against GlaxoSmithKline and Novartis over packaging for now discontinued painkiller Osteo Gel.
Sirtex Medical has reached a mid-trial agreement to resolve a shareholder class action that centred on the biotech company’s sales forecasts of its radiation treatment.
Noting the relevant three-year limitations provision was “quite unusal”, the judge overseeing a consumer class action against horse vaccine manufacturer Zoetis has given the class a chance to add a second applicant to the case, after it was revealed that part of the lead applicant’s claim was out of time.